[{"id":"efced585-c854-448e-8e56-41b641332188","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964543","created_at":"2023-07-31T17:08:45.535Z","updated_at":"2024-07-02T16:35:41.702Z","phase":"Phase 1/2","brief_title":"The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors","source_id_and_acronym":"NCT05964543","lead_sponsor":"QureBio Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Q-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2023-07-28"},{"id":"98a7e74d-3f89-4bec-823f-2c1fa742e162","acronym":"","url":"https://clinicaltrials.gov/study/NCT04856150","created_at":"2021-04-23T22:52:39.942Z","updated_at":"2024-07-02T16:35:41.787Z","phase":"Phase 1","brief_title":"A Study of Q-1802 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04856150","lead_sponsor":"QureBio Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Q-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-07-27"}]